Skip to content
Central Room UK

Patients Stopping Anti-Obesity Injections Put On Weight Far More Rapidly Than People Using Diet and Exercise

Image of pharmaceutical injection and weighing machine
Obesity treatment often requires long-term strategies.

New research suggests that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop traditional diet and exercise plans.

Published data in a major health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.

"Users buying these medications must be aware of the danger of quick rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.

This pace of regain suggests a reversion to starting mass in about one and a half years.

Weighing Therapies

The analysis, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.

Researchers emphasize that people who lose weight through diet and exercise generally see a more gradual weight regain—around 100 grams monthly—once they finish.

Explaining the Rapid Regain

Doctors believe the mechanism of the injections accounts for the heightened weight return.

The injections imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Long-term administration of the hormone concentrations several times higher than normal might result in the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Stopping of this hormone supplement leads to hunger is no longer kept in check, making binge eating far more likely."

A Chronic Condition?

Health authorities advise the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

Many experts say that, considering the high risk of weight regain, the therapy should be considered long-term.

This opinion is echoed by drug manufacturers, who say that the findings "underscore the persistent character of obesity," comparing it to managing conditions like high blood pressure.

Patient Testimonies

People who have discontinued the jabs report a intense return of cravings.

"It was like a trigger activating and I was suddenly starving," recalled one woman.

The struggle is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment.

Significant Interest

Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

  • Use is greater among females compared to males.
  • The 40s and 50s demographic shows the greatest level of interest.
  • Many access the medications through private prescriptions rather than public health services.

Finally, experts stress that while these medications are potent agents for weight loss, they are not a permanent solution and long-term success relies on integrated lifestyle support.

RI
About the author

Randy Ibarra

A tech journalist and digital strategist with over a decade of experience covering emerging technologies and consumer electronics.

Central Room UK

Type to search articles.